Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the lipid research clinics program follow-up study

T. L Bush; E BARRETT-CONNOR; L. D Cowan; M. H Criqui; R. B Wallace; C. M Suchindran; H. A Tyroler; B. M Rifkind

doi:10.1161/01.CIR.75.6.1102

Back

Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the lipid research clinics program follow-up study

Journal article

Open access

Peer reviewed

Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the lipid research clinics program follow-up study

T. L Bush, E BARRETT-CONNOR, L. D Cowan, M. H Criqui, R. B Wallace, C. M Suchindran, H. A Tyroler and B. M Rifkind

Circulation (New York, N.Y.), Vol.75(6), pp.1102-1109

1987

DOI: 10.1161/01.CIR.75.6.1102

PMID: 3568321

Files and links (1)

url

https://doi.org/10.1161/01.CIR.75.6.1102View

Published (Version of record) Open Access

Abstract

A cohort of 2270 white women, aged 40-69 years at baseline, were followed for an average of 8.5 years in the Lipid Research Clinics Program Follow-up Study. There were 44 deaths due to cardiovascular disease among the 1677 nonusers of estrogens and six cardiovascular disease deaths among the 593 estrogen users. The age-adjusted relative risk (RR) of cardiovascular disease deaths in users compared with nonusers was 0.34 (95% confidence limits 0.12 to 0.81). After multivariable adjustment for potential confounding factors (age, blood pressure, and smoking), the estimated RR for estrogen use was 0.37 (95% confidence limits 0.16 to 0.88). Analyses were done to explore whether these results could be due to selection bias for estrogen use. However, the prevalence of cardiovascular disease at baseline was slightly higher in estrogen users (12%) than in nonusers (10%); furthermore, the exclusion of all women with prevalent cardiovascular disease at baseline did not alter the apparent protective effect of estrogen use on cardiovascular disease mortality (RR = 0.42, 95% confidence limits 0.13 to 1.10). Additional analyses examining the complex association between estrogen use, lipoprotein levels, and cardiovascular disease mortality suggest that the protective effect of estrogen is substantially mediated through increased high-density lipoprotein levels.

Cardiovascular System

Biological and medical sciences

Medical sciences

Miscellaneous

Pharmacology. Drug treatments

Details

Title: Subtitle: Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the lipid research clinics program follow-up study
Creators: T. L Bush - University of Oklahoma
E BARRETT-CONNOR - University of Oklahoma
L. D Cowan - University of Oklahoma
M. H Criqui - University of Oklahoma
R. B Wallace - University of Iowa
C. M Suchindran - Oklahoma Medical Research Foundation
H. A Tyroler - University of Oklahoma
B. M Rifkind - University of Oklahoma
Resource Type: Journal article
Publication Details: Circulation (New York, N.Y.), Vol.75(6), pp.1102-1109
DOI: 10.1161/01.CIR.75.6.1102
PMID: 3568321
NLM abbreviation: Circulation
ISSN: 0009-7322
eISSN: 1524-4539
Publisher: Lippincott Williams & Wilkins
Language: English
Date published: 1987
Academic Unit: Epidemiology; Injury Prevention Research Center; Internal Medicine
Record Identifier: 9984363593402771

Metrics

17 Record Views

1238 Times Cited - Web of Science

See more details